ABM Respiratory Care to scale US sales efforts
By HME News Staff
Updated 10:23 AM CDT, Mon June 22, 2026
EAGAN, Minn. – ABM Respiratory Care has successfully closed its Series B financing round, raising $14.8 million – well above its $12 million target.
The funds will be used to accelerate the commercialization of BiWaze Clear, ABM's latest airway clearance system designed for both hospital and home use. This includes scaling U.S. sales efforts, investing in clinical research, and enhancing patient engagement and digital health capabilities.
"This investment marks a pivotal moment for ABM Respiratory Care as we expand access to our respiratory therapy platform and bring transformative solutions into more homes and hospitals," said Greg Miller, CEO of ABMRC. "We're grateful for the support of our new and existing investors who are excited about our vision for intelligent, connected therapies of people struggling to breathe."
The oversubscribed round was led by Peter Soderberg, ABMRC's chairman of the board and managing partner of Worthy Venture Resources, LLC, who more than doubled his investment in the company. The round also included significant participation from Blue Wave Capital, LLC, an investment firm focused on the U.S. health care sector with one of the co-founding partners joining the board, alongside other new and existing investors.
ABM says BiWaze Clear helps people clear their lungs more efficiently by combining three therapies in one: lung expansion, high-frequency oscillations and aerosol delivery with an integrated nebulizer.
Comments